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1. Introduction 
Pancreatogenous hypoglycemic syndrome (PHS) is a heterogeneous disorder that occurs as 
a consequence of inappropriate and unregulated secretion of insulin by pancreatic β-cell 
tumors (insulinomas) or by nesidiodysplastic β-cells presenting as non-insulinoma 
pancreatogenous hypoglycemic syndrome (NIPHS).  NIPHS, formerly termed adult 
nesidioblastosis, is characterized by postprandial hypoglycemia and negative prolonged 
fasts, and yields negative perioperative localization studies for insulinoma but positive 
intra-arterial calcium stimulation (IACS) tests as well as nesidioblastosis in the gradient-
guided resected pancreas (Service et al., 1999a; Won et al., 2006). NIPHS is an increasingly 
recognized entity and appears to develop much more frequently in patients who have 
undergone either a Billroth II operation for peptic ulcer diseases or a Roux-en-Y gastric 
bypass procedure for medically complicated obesity (Service et al., 2005; Patti et al., 2005).  
Even though the histology of the resected pancreatic tissues from those patients resemble 
some of the histologic features observed in patients of congenital hyperinsulinism (CHI), in 
which genetic mutations in the 2 subunits (Kir6.2 and SUR 1) of the pancreatic β-cell ATP-
sensitive potassium channel (KATP) are observed (Kapoor et al., 2006), screening for similar 
mutations in those patients has proven unsuccessful (Service et al., 1999; Patti et al., 2005).  
Although the existence of post-gastric bypass NIPHS as a discrete entity has been strongly 
questioned (Meier et al., 2006), several lines of evidence—the neuroglycopenic nature of 
spells, the usual unresponsiveness to dietary modification, and the very high recurrence rate 
(up to 87%) after gradient-guided pancreatectomy (Vanderveen et al., 2010)—suggest 
functional as well as structural abnormalities of the disorder. 
Traditionally, PHS in adults is most commonly caused by circumscribed solitary or multiple 
insulinomas, while in 0.5-5% of patients, localized or diffuse proliferation of islet cells 
budding from pancreatic ducts (nesidioblastosis) has been defined (Fajans & Vinik 1989).  
With increasing utilization of IACS test, however, evidence shows that NIPHS has been 
found to account for 40-50% of all the patients with PHS (Starke et al., 2006; Thompson 
2007).  In our hospital, we routinely performed IACS tests for patients with documented 
hyperinsulinemic hypoglycemia, and during the past 15 years we found roughly an equal 
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incidence of insulinoma and NIPHS (Won et al., 2006), among the latter one-third had had 
gastric bypass surgery that was not bariatric-related.  
2. Clinical presentations 
The hypoglycemic symptoms are usually divided into adrenergic and neuroglycopenic 
symptoms.  The sympathetic adrenergic symptoms include tachycardia, palpitations, 
sweating, tremor, and anxiety.  The glucose deprivation of central nervous system (CNS) 
results in neuroglycopenic symptoms including behavioral changes, confusion, weakness, 
fatigue, loss of consciousness, amnesia, dizziness, blurry vision, diplopia, paresthesia, 
seizures, and coma (Fajans & Vinik 1989).  These symptoms can occur during fasting, after 
exercise, or postprandially (3-5 hours after meal).  Although the adrenergic symptoms are 
not unique to hypoglycemia, the possibility of neuroglycopenia should always be suspected 
in patients whose adrenergic symptoms are followed by spells of disturbed CNS functions, 
patients whose symptoms occur in the setting of a documented absolute hypoglycemia 
(plasma glucose ≤ 45 mg/dl; 2.8 mmol/l), and patients whose symptoms are relieved by 
glucose administration.  A detailed history to ascertain the type of symptoms, the frequency 
of spells and its relationship to meals, and history of gastric bypass surgery should be 
obtained.  Furthermore, clinical evidence of neuroglycopenia should be highly suggestive of 
organic hyperinsulinism, such as PHS, and warrants meticulous attentiveness and further 
testing until proven otherwise (Dizon et al., 1999).  Approximately one-fourth of patients 
with insulinoma develop only neuroglycopenic symptoms (Fajans & Vinik 1989; Dizon et 
al., 1999).   
Insulinoma is typically associated with fasting hypoglycemia, but may occur during both 
fasting and in postprandial states or even exclusively postprandially (Placzkowski et al., 
2009).  In contrast, NIPHS is often manifested as postprandial hypoglycemia, although 
fasting hypoglycemia can also occur.  In a few of our NIPHS patients, persistent 
hypoglycemia during both fasting and postprandial periods requiring continuous infusion 
of dextrose to prevent neuroglycopenia was observed.   
3. Diagnosis 
The diagnosis of PHS requires biochemical confirmation of inappropriately elevated plasma 
insulin concentrations in the settings of absolute hypoglycemia, which may occur 
spontaneously or can be provoked (Service 1999). The diagnostic criteria for 
hyperinsulinemia consist of a plasma insulin level ≥ 6 µU/ml (36 pmol/l), a plasma C-
peptide ≥ 0.6 ng/ml (200 pmol/l), or a plasma proinsulin ≥ 5 pmol/l, and a plasma β-
hydroxybutyrate ≤ 2.7 mmol/l at the time of hypoglycemia (plasma glucose ≤ 45 mg/dl or 
less) (Service 1999b).  Nevertheless, with the development of the more sensitive and highly 
specific assay for insulin, the immunochemiluminometric assay (ICMA), an insulin level of ≥ 
3 µU/ml (18 pmol/l) has been suggested as the criterion for hyperinsulinemia (Service 
1999b).  It is therefore crucial to measure, in addition to insulin, the concentrations of plasma 
C-peptide (a marker of endogenous insulin production), proinsulin, and ketone body (an 
indicator of insulin action) concurrently during a symptomatic hypoglycemia, as occasional 
insulinoma cases have reported persistent low serum insulin levels as determined by ICMA, 
despite the elevated C-peptide and/or proinsulin concentrations (Chia & Saudek 2003; 
Coelho et al., 2009).  Also, it is prudent to measure the level of insulin secretagogues (i.e., 
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sulfonylureas and glinides), if available, to differentiate the factitious hypoglycemia;and 
insulin autoantibody to identify and exclude the insulin autoimmune syndrome, a rare 
disorder reported to occur primarily among persons of Japanese ancestry (Comi 1993) .  Our 
experience shows that, during hypoglycemic spells, the insulin levels tend to be higher in 
patients with insulinoma than in patients with NIPHS, in whom the detected insulin 
concentration may be a little higher than the aforementioned diagnostic criteria. 
4. Laboratory tests  
4.1 72 h fast  
The 72 h supervised fast remains the gold standard for the diagnosis of insulinoma as the 
test enables the clinical demonstration of Whipple’s triad: symptoms and signs consistent 
with hypoglycemia, a concomitant plasma glucose level of 45 mg/dl or less, and 
reversibility of symptoms with administration of glucose (Service & Natt 2000).  In addition, 
the test provides biochemical confirmation of unsuppressed insulin secretion in the settings 
of hypoglycemia by measuring plasma insulin, C-peptide, proinsulin, and β-
hydroxybutyrate concentrations simultaneously, as aforementioned.  In most reports, one-
third of patients with insulinoma develop symptoms within 12 hours, two-thirds within 24 
hours, 95% in 48 hours, and 99% in 72 hours (Service & Natt 2000).  A recent study suggests 
that a 48-h fast may be an alternative, with a sensitivity rate of 95% (Hirshberg et al., 2000).  
In our hospital, we routinely perform the 48-h prolonged fast.  As expected, most patients 
with NIPHS, by definition, do not develop hypoglycemia during a 72 h prolonged fast.  
4.2 The 5-hour oral glucose tolerance test (OGTT) 
In contrast to the 72 h fast testing, the OGTT test may offer biochemical evidence of 
postprandial hypoglycemia associated with clinical symptoms and signs of 
neuroglycopenia, which may be missed in the supervised 72 h fast, though an abnormal 
OGTT is not helpful in the diagnosis or differential diagnosis of organic hyperinsulinism 
(Service 1999a).  Interestingly, very few cases of insulinoma show signs of glucose-induced 
hypoglycemia alone (Wiesli et al., 2002; Kar et al., 2006).   
4.3 Insulin/glucose (I/G) ratio or amended I/G ratio 
These measurements are no longer applied to the diagnosis of organic hyperinsulinism as 
currently most insulin assays have been replaced by the more specific ICMA technique 
worldwide. 
5. Image studies 
Because of the small size (90% tumors usually less than 2 cm in size), potential multiplicity, 
and possible throughout the whole pancreas, preoperative localization of tumors is very 
important and essential in determining prognosis and appropriate surgical intervention. 
There are a variety of preoperative imaging modalities for the detection of insulinomas. 
However, no single one imaging examination could localize tumors in all patients. Most 
experienced endocrine surgeons obtain one or more localization tests before treatment is 
performed. In choosing the localization technique, specific tumor characteristics need to be 
considered. 
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a. Most insulinomas are vascular and visualized in arterial phase imaging. 
b. Most tumors are intrapancreatic. 
c. 80 – 90% are solitary and 80% less than 2 cm in diameter. 
d. Distributed equally within the head, body and tail of the pancreas. 
e. Multiple tumors are found in only 8% of patients associated with MEN-1. 
5.1 Preoperative transabdominal ultrasound 
Just like other abdominal diseases, transabdominal ultrasound is the most convenient 
imaging modality to examine the pancreatic insulinomas. It is noninvasive, radiation free, 
and readily available. However, the pancreas is deeply located in the abdomen and most 
patients with insulinoma are obese due to frequent snacking to resolve hypoglycemic 
symptoms. To fully investigate the whole pancreas demands meticulous technique. Besides 
the usual supine position, placing the patient in recumbent or upright oblique position may 
be necessary. Using the fluid-filled stomach or the spleen as acoustic window is also useful 
to examine the body and tail of pancreas (Galiber et al.,1988; Gorman et al., 1986). 
Usually, insulinoma is detected as a solitary, rounded, well-defined, hypoechoic mass with 
smooth outlines (Galiber et al.,1988). Gorman and colleagues reported 10% insulinoma either 
isoechoic or hyperechoic to surrounding parenchyma that may be due to normal pancreatic 
parenchyma.  It is less echogenic in younger patients than in older ones (Gorman et al., 1986). 
The ultrasound is operator dependent; thus, different detection rates were reported. 
Guettier and colleagues reported only a 14% accurate localization rate, a 72% false negative 
and a 14% false positive rates (Guettier et al., 1986). Grant reported their Mayo Clinic 
experience from July 1982 through October 2004 with a 65% sensitivity and a 91% positive 
predictive value (Grant, 2005). Not surprisingly, the bigger the tumor ,the easier it is to be 
detected. Böttger and colleagues reported a sensitivity of 43% for tumors less than 1 cm in 
diameter, 67% for tumors between 1 and 1.5 cm, and 80% for tumors larger than 1.5 cm 
(Böttger et al., 1990). Kuzin and colleagues reported rates of 10%, 21.4% and 53.8% for 
tumors less then 1 cm,1 to 2 cm and larger than 2 cm, respectively (Kuzin et al., 1998). They 
also found tumor location may affect the sensitivity of this test, with a 50% detection rate for 
tumor at pancreatic body, 16.7% for head and 23% for tail (Kuzin et al., 1998). 
5.2 Endoscopic ultrasound (EUS) 
Compared with transabdominal ultrasound, EUS is close to pancreas and can use high-
frequency probe that improves the image resolution and increases the detection rate of 
insulinoma. The appearance of insulinomas in EUS is similar to that in transabdominal 
ultrasound. Most published series reported high sensitivity. Rösch and colleagues described 
a sensitivity of 82% (Rösch et al., 1992). Nikfarjam and colleagues reported 92% (Nikfarjam 
et al., 2008). But Druce and colleagues reported only 65.4% (Druce et al., 2010). This 
discrepancy implies the importance of expertise to carry out the procedure. Tumor location 
is another important factor. To detect an insulinoma in the pancreatic head portion is easier 
than one in the tail. Schumacher et al. had a 83% sensitivity for tumors at the head and 37% 
at the tail (Schumacher et al., 1996). 
5.3 Computed tomography (CT) 
CT is widely used to scan the pancreatic insulinoma. The reported sensitivity rate varied 
with different techniques. The conventional CT scan had low sensitivity with a range of 16 – 
72% (Chatziioannou et al., 2001). There are at least two reasons to account for the low 
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detection rate. First, most insulinomas are small that conventional CT may skip the tumors. 
Second, small insulinomas appear similar density as normal parenchyma in pre-contrast and 
post-contrast delayed scan of conventional CT. With modern multidetector CT with dynamic 
contrast study, the above mentioned problems can be solved. After taking non-contrast study 
with thick slices (5–8 mm), biphasic images are taken after intravenous injection of 120–150 ml 
non-ionic contrast medium at the rate of 3-5 ml/sec with power injector. The arterial phase is 
taken about 30 seconds after injection and venous phase at 70 seconds. Thin slices and 
reformatted images may help to demonstrate smaller lesions (Chung et al., 1997). Nikfarjam 
and colleagues found the sensitivity rate increased from 24% before 1997 to 80% between 1994 
and 2007 (Nikfarjam et al., 2008). Most insulinomas show isodensity nodule in pre-contrast 
scan and high density in the arterial phase images. Atypical CT appearances of insulinomas 
include a high density mass in pre-contrast CT scan, low density mass in post contrast scan, 
cystic or calcified mass (Chatziioannou et al., 2001). 
5.4 Magnetic resonance imaging (MRI) 
Modern MRI provides a high sensitive test in the localization of insulinoma. High field (1.5 
T or 3 T) magnet combined with torso phased-array coil is used. Antiperistaltic agents may 
be used to decrease artifact caused by bowel movement. The protocol includes axial T1 and 
spin echo image with and without fat suppression, and spoiled gradient-echo (GRE) image 
before and after intravenous administration of gadolinium (Thoeni et al., 2000). Insulinomas 
usually show a low signal intensity in T1-weighted image and high in T2-weighted image, 
and marked enhancement after intravenous gadolinium administration. With modern MRI, 
the detection rates of 70% (Nikfarjam et al., 2008), 75% (Druce et al., 2010), and 85% (Thoeni 
et al., 2000) had been reported. The MRI technique is in constant  evolution. Recently, the 
diffusion weighted image technique is applied to examine the abdomen. It may improve the 
detection of pancreatic insulinomas (Lee et al., 2008). 
5.5 Angiography 
Though angiography was considered also sensitive to localize insulinomas, it was rarely 
performed alone today in this hospital, and usually was combined with hepatic venous 
sampling. To perform angiography, a catheter is advanced through femoral artery and 
selected into the arteries that supplying the pancreas, including the celiac, superior 
mesenteric, splenic and gastroduodenal arteries. Modern angiographic suite is 
armamentarium with digital subtraction technique that will improve the sensitivity of this 
test. However, antiperistaltic agents may be necessary to suppress bowel movement which 
causes motion artifact (Jackson, 2005). Besides, different projections are mandatory to avoid 
overlapping with other organ, such as the spleen, that may interfere with the blush of 
insulinoma. Classical angiographic picture of an insulinoma is a well defined blushing 
appearing in early arterial phase and persist to venous phase. But hypovascular insulinomas 
are not uncommon because of their small sizes. Fulton and colleagues reported 9 of 24 
insulinomas were hypovascular (Fulton et al., 1975). The reported detection rate of 
angiography ranged from 35% (Doherty et al., 1991) to 100% (Geoghegan et al., 1994). 
5.6 Percutaneous transhepatic portal venous sampling (PTPVS) 
The concept of PTPVS is that insulinomas secrete insulin which would be drained into 
adjacent venous system. The closer to the insulinoma, the higher the concentration of insulin 
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would be detected. After puncturing the branch of right portal vein, a catheter with side-
hole at tip was advanced into the splenic vein and superior mesenteric vein. Venography 
was taken first as a map. Then, samplings were taken along the splenic, superior and 
inferior mesenteric veins as well as the portal trunk at 1 to 1.5 cm intervals. Pancreatic veins 
were also sampled when possible (Cho et al., 1982). PTPVS was highly accurate and 
considered to be the gold standard for this purpose (Nikfarjam et al., 2008; Vinik et al., 
1991). However, severe complications, which mainly related to catheterizing the portal vein, 
are not infrequent. Miller and colleagues reported a rate of 6% severe complications (Miller 
et al., 1992). For this reason and the development of other less invasive modality, i.e. 
selective intra-arterial calcium stimulation with hepatic venous sampling, PTPVS is rarely 
performed nowadays. 
5.7 Selective intra-arterial calcium stimulation (IACS) with hepatic venous sampling 
In 1987, Imamura and colleagues described a novel method of intra-arterial injection of 
secretin and then sampling blood from hepatic vein to localize gastrinoma in patients with 
Zollinger-Ellisson Syndrome (Imamura et al., 1987). In 1991, Doppman and colleagues 
adopted the concept but using calcium as secretagogue to localize insulinoma in four cases 
(Doppman et al. 1991). To perform IACS, a catheter with side-hole at the tip is threaded 
through femoral vein into right hepatic vein. After selective angiography, 10% calcium 
gluconate diluted with saline to equivalent to 0.0125 mmol/kg (0.025 mEq/kg) is injected as 
quickly as possible but not spilled into adjacent vessles to avoid bias. In obese patients, the 
dose is adjusted to 0.005mmol/kg. Blood samples are obtained from the right hepatic vein 
before and 30, 60, 90, 120, and 180 seconds after injection of calcium. All the arteries 
supplying pancreas should be studied that including superior mesenteric, gastroduodenal, 
and splenic arteries. Sometimes, dorsal pancreatic artery is also studied if it is large enough 
to be catheterized safely. A two-fold or greater increase of insulin above baseline indicates a 
positive result. A positive result in superior mesenteric artery or gastroduodenal artery 
means the lesion at pancreatic head or uncinate process, while in splenic artery means 
pancreatic body or tail. To further differentiate tumor location in body or tail, two sets of 
splenic artery samplings are collected. One is at proximal injection, another is distal to the 
pancreatic magna artery. If both are positive, the lesion is at pancreatic tail. If only proximal 
one is positive, the lesion is at pancreatic body. Besides the above mentioned arteries, proper 
hepatic artery is also studied to search the possibility of liver metastasis. The time between 
two calcium injections should be at least 5 minutes apart to allow the possible stimulated 
elevation of insulin level to return to its baseline (Jackson, 2005). Since its development, 
IACS is considered the most reliable preoperative localization modality for insulinoma. In 
most reported series, successful rates were more than 90% (Jackson, 2005) .Diazoxide that is 
used to treat hyperinsulinemia should be suspended before IACS test as it may affect the 
result of the test (Doppman et al., 1991). 
Besides insulinomas, beta-cell hyperfunction, the so-called nesidioblastosis, is another 
important cause of PHS. Since most nesidioblastosis did not form discrete nodule, the non-
invasive image studies are usually negative (Raffel et al., 2007; Service et al., 1999a; Starke et 
al., 2006). But the IACS test always shows positive result and is an important clue to the 
diagnosis of nesidioblastosis. Meanwhile, if surgical treatment is to be performed, the 
gradient-guided resection according to the results of IACS test is mandatory (Thompson et 
al., 2000; Tseng et al., 2007). 
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5.8 Somatostatin receptor scintigraphy (SRS) 
The somatostatin receptor scintigraphy (OctreoscanTM), which uses Indium-111 
pentetreotide as a traceable somatostatin analog that predominantly binds to receptor 
subtypes, sst2 and sst5 (Bertherat et al., 2003), serves as a functional imaging modality for 
neuroendocrine tumors and some non-neuroendocrine tumors which contain somatostatin 
receptors. 
The diagnostic accuracy of the SRS is affected by the size and presence of different receptor 
subtypes of the tumors. The sensitivity of SRS in detecting insulinoma is reported to be as 
low as 50-60% (Balon et al., 2001; Mirallie et al., 2002), but the positive predictive value is 
high (Proye et al., 1998). 
The SRS serves as a complementary role in the localization of an insulinoma when the 
diagnosis is established but undetectable or equivocal on CT or MRI. 
6. Treatment 
6.1 Medical treatment 
For the insulinoma patients surgery is not amenable or is contraindicated, and for those with 
unresectable disease, medical treatment with diazoxide, a β-cell KATP channel agonist to 
inhibit insulin secretion, can be used with a reported effective rate of 97% (Gill et al., 1997).  
The usual dosage range is 150 to 450 mg daily, given orally twice or thrice a day.  Side 
effects include nausea, hypertrichosis, and sodium retention.  The addition of a 
benzothiadiazine diuretics, such as chlorothiazide, can combat the edema and potentiate the 
hyperglycemic effect of diazoxide (Fajans & Vinik 1989).  Octreotide, a long-acting 
somatostatin analog that acts mainly via the somatostatin receptor subtype 2, is sometimes 
effective (Vezzosi et al., 2005).  
Once the diagnosis of NIPHS in the patient is confirmed by IACS, medical treatment with 
diazoxide should be tried first.  Our limited experience found that almost all the patients, 
with or without a previous gastric bypass surgery, responded satisfactorily, with alleviation 
of neuroglycopenic episodes presumably in those with intact function of β-cell KATP channel, 
which the action of diazoxide requires (Won et al., 2006).  Whether octreotide or the newer 
analog, pasireotide (SOM230), is effective in patients with NIPHS is unclear and requires 
further study. 
6.2 Surgical treatment 
Surgical resection remains the treatment of choice for insulinomas. Usually, the successful 
rate of surgical treatment is over 90% in experienced hands. However, over resection of the 
pancreas may lead to diabetes which causes another problem affecting the patients’ quality 
of life .With the advancement in imaging technology, increase in knowledge as well as 
improvement in surgical technique, blind resection for an unlocalized insulinoma is no more 
acceptable. Various modalities of resection are available for the surgical treatment of 
insulinomas. Enunciation is usually employed for an insulinoma superficially located and 
away from the main pancreatic duct either in the head or body portion of the pancreas. The 
postoperative occurrence rate of pancreatic fistula varied from 18 to 57%. Enucleation of the 
pancreatic tail insulinomas is also feasible in selective conditions such as a pedunculated or 
a small bulging tumor from pancreatic surface; or a clearly visible image of 2 to 3 mm 
distance between the tumor and main pancreatic duct. In the author's opinion, enucleation is 
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always first considered and evaluated before a resection of pancreas. If feasible, it causes 
less damage, avoids sacrificing islets in the pancreatic tail and saves time for operation. A 
distal pancreatectomy (40% distal pancreas resection) is done for multiple or big 
insulinomas ; or the tumor is attached to the pancreatic duct. The spleen should be 
preserved as possible; A Whipple’s operation is rarely necessary for pancreatic head 
insulinoma unless it is big, deep or located near the main duct; Subtotal pancreatectomy 
(60~85% distal pancreatctomy) with enucleation of tumors in the head was advised for 
MEN-1 associated insulinomas because of its multiple and diffuse lesions before the IACS 
test was popular (Thompson 1995). Our recent experiences showed that a solitary 
insulinoma disease may exist in MEN-1 patients, and distal pancreatectomy achieved 
euglycemia for more than 10 years. Individualized judgment according to the IACS 
insulin gradients is mandatory to avoid over resections and ensuing sequellae, although in 
the published large series (Tonelli et al., 2005; Bartsch et al., 2005; Norton et al., 2006) most 
patients needed an extended distal pancreatectomy and enucleation of tumors in the 
head.  
With repeated emphasis on the management of hypoglycemia in medical education as well 
as increased alertness of physicians at emergency department, more and more patients had 
diagnosis of spontaneous pancreatogenous hypoglycemia at its early presentation. It is our 
recommendation that image studies are done to localize the lesion instead of screening for 
diagnosis. However, despite the advancement in imaging technology, up to 25% of 
insulinomas remain occult preoperatively (Norton 1989). An occult insulinoma is defined as 
biochemically proven tumor with indeterminate anatomical site before operation. It should 
not prohibite the physicians from referring to surgery because intraoperative 
ultrasonography(IOUS) and palpation (96~100% sensitivity) by experienced surgeon may 
help to find out the tumor. A preoperative IACS test is helpful to indicate the region the 
tumor is located. It is especially useful in re-do operations or in patients with previous 
episodes of pancreatitis. In both situations dense peripancreatic adhesion usually exists and 
causes difficulties in dissection. Following the guidance of IACS test, a limited regional 
exploration may help to save operation time and prevent post-operative pancreatitis due to 
over manipulation (Tseng et al., 2007). 
In case, IOUS and palpation failed to find the lesion, we recommend a regional resection of 
pancreatic tail (40%) or tail and body (80-85%) as suggested by the insulin gradients in the 
splenic artery alone or plus SMA. This is different from a blind resection and is helpful in 
the surgical treatment of adult NIPHS. Our previous report has shown its advantage over a 
subtotal pancreatectomy in terms of post-operative diabetes (Lee et al., 2002). However, 
long-term follow up is needed to observe any recurrence.   
In summary, the goal of surgical treatment for PHS should aim at post-operative euglycemia 
and long term recurrence free. A blind distal pancreatectomy or an improper extensive 
subtotal pancreatectomy should not be performed. The IACS test plus IOUS is a good 
resection guide in the treatment of PHS. Surgical intervention for NIPHS is reserved for 
those refractory to medical treatment. 
7. Conclusion 
Spontaneous pancreatogenous hypoglycemic syndrome is a rare disease. With typical 
clinical presentation and compatible laboratory tests, it is not difficult for early diagnosis. 
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With pre-operative localization and intra-operative palpation as well as the use of 
intraoperative ultrasonography, blind resection of the distal pancreas is no more accepted. 
The cure rate of surgical treatment for insulinomas is usually more than 90%. Medical 
treatment is for those with high operation risk, previous failure of pre-operative and intra-
operative localization or diffuse islet cell hyperplasia as indicated in the selective intra-
arterial calcium stimulation test. 
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